September 2018 - Cytochrome P450 3A4 Inhibitors drug patent information, international generic entry, market access

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-002	Mar 30, 2009		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				➤ Sign Up
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-002	Mar 30, 2009		RX	Yes	Yes	➤ Sign Up	➤ Sign Up			Y	➤ Sign Up
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-003	Jul 9, 2010		RX	Yes	No	➤ Sign Up	➤ Sign Up				➤ Sign Up
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-001	Mar 30, 2009		RX	Yes	No	➤ Sign Up	➤ Sign Up				➤ Sign Up
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-003	Jul 9, 2010		RX	Yes	No	➤ Sign Up	➤ Sign Up			Y	➤ Sign Up
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-001	Mar 30, 2009		RX	Yes	No	➤ Sign Up	➤ Sign Up			Y	➤ Sign Up
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-004	Mar 30, 2012		RX	Yes	No	➤ Sign Up	➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration